Chronic Fatigue Syndrome Treatment Market

Chronic fatigue syndrome, also known as Myalgic encephalomyelitis, is a chronic disease which lasts for six months and affects the central nervous system and the immune system. The disease leads to musculoskeletal disorders, impairment of long term memory, and disturbed sleep patterns. This results in substantial decline in social, occupational, educational, and personal activity among patients. There are no specific biomarkers or tests to diagnose chronic fatigue syndrome. Symptoms include sore throat, muscle pain, headache, and fatigue, which continues for months or years.

Chronic Fatigue Syndrome Treatment Market contains market size and forecasts of Chronic Fatigue Syndrome Treatment in Global, including the following market information:

Global Chronic Fatigue Syndrome Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chronic Fatigue Syndrome Treatment market was valued at 276.8 million in 2021 and is projected to reach US$ 374.2 million by 2028, at a CAGR of 4.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Pain Relievers and NSAIDs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Fatigue Syndrome Treatment include Pfizer, Teva, Mylan, Depomed, Mallinckrodt Pharmaceuticals, Eli Lilly, Bayer, Novartis and Sun Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Chronic Fatigue Syndrome Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Fatigue Syndrome Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Fatigue Syndrome Treatment Market Segment Percentages, by Type, 2021 (%)

Pain Relievers and NSAIDs

Antidepressant and Antipsychotic Drugs

Antimicrobial and Immunomodulatory Drugs

Global Chronic Fatigue Syndrome Treatment Market, by Distribution Channel, 2017-2022, 2023-2028 ($ millions)

Global Chronic Fatigue Syndrome Treatment Market Segment Percentages, by Distribution Channel, 2021 (%)

Hospital

Retail Pharmacy

Other

Global Chronic Fatigue Syndrome Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Fatigue Syndrome Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Fatigue Syndrome Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chronic Fatigue Syndrome Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Teva

Mylan

Depomed

Mallinckrodt Pharmaceuticals

Eli Lilly

Bayer

Novartis

Sun Pharmaceutical

Astrazeneca

Lundbeck

Arbor Pharma